Heart and Trauma Research Laboratory, College of Medicine and Dentistry, James Cook University, Queensland, Queensland 4811, Australia.
Mil Med. 2024 Aug 19;189(Suppl 3):268-275. doi: 10.1093/milmed/usae090.
Non-compressible torso hemorrhagic (NCTH) shock is the leading cause of potentially survivable trauma on the battlefield. New hypotensive drug therapies are urgently required to resuscitate and protect the heart and brain following NCTH. Our aim was to examine the strengths and limitations of permissive hypotension and discuss the development of small-volume adenosine, lidocaine, and Mg2+ (ALM) fluid resuscitation in rats and pigs.
For review of permissive hypotension, a literature search was performed from inception up to November 2023 using PubMed, Cochrane, and Embase databases, with inclusion of animal studies, clinical trials and reviews with military and clinical relevance. For the preclinical study, adult female pigs underwent laparoscopic liver resection. After 30 minutes of bleeding, animals were resuscitated with 4 mL/kg 3% NaCl ± ALM bolus followed 60 minutes later with 4 h 3 mL/kg/h 0.9% NaCl ± ALM drip (n = 10 per group), then blood transfusion. Mean arterial pressure (MAP) and cardiac output (CO) were continuously measured via a left ventricular pressure catheter and pulmonary artery catheter, respectively. Systemic vascular resistance (SVR) was calculated using the formula: 80 × (MAP - CVP)/CI. Oxygen delivery was calculated as the product of CO and arterial oxygen content.
Targeting a MAP of ∼50 mmHg can be harmful or beneficial, depending on how CO and SVR are regulated. A theoretical example shows that for the same MAP of 50 mmHg, a higher CO and lower SVR can lead to a nearly 2-fold increase in O2 supply. We further show that in animal models of NCTH, 3% NaCl ALM bolus and 0.9% NaCl ALM drip induce a hypotensive, high flow, vasodilatory state with maintained tissue O2 supply and neuroprotection. ALM therapy increases survival by resuscitating the heart, reducing internal bleeding by correcting coagulopathy, and decreasing secondary injury.
In rat and pig models of NCTH, small-volume ALM therapy resuscitates at hypotensive pressures by increasing CO and reducing SVR. This strategy is associated with heart and brain protection and maintained tissue O2 delivery. Translational studies are required to determine reproducibility and optimal component dosing. ALM therapy may find wide utility in prehospital and far-forward military environments.
非压缩性躯干出血性(NCTH)休克是战场上潜在可生存创伤的主要原因。迫切需要新的低血压药物治疗方法来复苏和保护 NCTH 后的心脏和大脑。我们的目的是检查允许性低血压的优缺点,并讨论在大鼠和猪中进行小容量腺苷、利多卡因和 Mg2+(ALM)液复苏的发展。
为了回顾允许性低血压,从现在开始到 2023 年 11 月,使用 PubMed、Cochrane 和 Embase 数据库进行了文献检索,纳入了具有军事和临床相关性的动物研究、临床试验和综述。对于临床前研究,成年雌性猪接受腹腔镜肝切除术。出血 30 分钟后,动物用 4 mL/kg 3% NaCl 加 ALM 弹丸复苏,60 分钟后用 4 小时 3 mL/kg/h 0.9% NaCl 加 ALM 滴注(每组 10 只),然后输血。通过左心室压力导管和肺动脉导管分别连续测量平均动脉压(MAP)和心输出量(CO)。全身血管阻力(SVR)通过公式计算:80×(MAP-CVP)/CI。氧输送计算为 CO 和动脉血氧含量的乘积。
目标 MAP 约为 50mmHg 可能有害或有益,具体取决于 CO 和 SVR 的调节方式。理论示例表明,对于相同的 MAP 为 50mmHg,较高的 CO 和较低的 SVR 可导致 O2 供应增加近 2 倍。我们进一步表明,在 NCTH 的动物模型中,3%NaCl-ALM 弹丸和 0.9%NaCl-ALM 滴注会导致低血压、高流量、血管扩张状态,同时保持组织 O2 供应和神经保护。ALM 治疗通过复苏心脏、纠正凝血障碍减少内出血以及减少继发性损伤来增加存活率。
在 NCTH 的大鼠和猪模型中,小容量 ALM 治疗通过增加 CO 和降低 SVR 在低血压压力下复苏。这种策略与心脏和大脑保护以及维持组织 O2 输送有关。需要进行转化研究以确定可重复性和最佳成分剂量。ALM 治疗可能在院前和远前军事环境中具有广泛的应用。